The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Nivolumab-AVD & BrECADD in Hodgkin lymphoma: clinical considerations for these regimens
Stephen Ansell, MD, PhD, Mayo Clinic, Rochester, MN, comments on the debate surrounding the choice between nivolumab-AVD and BrECADD as standard therapies in Hodgkin lymphoma. Dr Ansell also notes that while combining nivolumab and brentuximab vedotin without chemotherapy seems promising, the durability of responses has been disappointing, making this approach less favorable. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
